$44.49
0.74% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
CA98420N1050
Symbol
XENE

Xenon Pharmaceuticals Inc. Stock News

Positive
Seeking Alpha
16 days ago
Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder treatment. XENE's $555M cash position supports operations into 2027, reducing near-term financing risk despite increased R&D and G&A expenses. Azetukalner's Phase 3 epilepsy and depression trials, strong long-term efficacy, and unique mechanism offer significant commercia...
Neutral
Seeking Alpha
24 days ago
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript
Neutral
GlobeNewsWire
29 days ago
VANCOUVER, British Columbia and BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced new data highlighting its commitment in epilepsy, including interim 48-month data from its ...
Neutral
GlobeNewsWire
30 days ago
VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 3...
Neutral
GlobeNewsWire
about one month ago
VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its data presentations at the Ame...
Positive
Proactive Investors
about one month ago
Polarean Imaging PLC's (AIM:POLX, OTC:PLLWF) stock popped 12% to 0.14p on Monday after the company cleared a major technical hurdle in its bid to get Xenon-based lung scans into more hospitals. Philips has signed off on Polarean's XENOVIEW 3T chest coil, confirming it plays nicely with the Dutch giant's next wave of 3-tesla MRI scanners.
Neutral
GlobeNewsWire
about one month ago
Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner Data will also highlight the impact of depression and burden of titration on patients with epilepsy, as well as new pre-clinical data from the Company's Na V 1.1 program in Dravet syndrome VANCOUVER, British Columbia and B...
Positive
Proactive Investors
about one month ago
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has secured its first foothold in Asia after National Taiwan University Hospital agreed to install one of the company's Xenon MRI research systems. The deal has been arranged through Philips, Polarean's long-standing strategic partner, and supported by Sumtage, the company's newly appointed distributor in Taiwan.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today